^
    Back
    Association details:
    Biomarker:SOX2 overexpression
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Pharmacol Rep
    Title:

    Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer

    Published date:
    01/09/2022
    Excerpt:
    Analysis of clinically relevant data indicated that expression of stemness factor, SOX2, was positively correlated with CDK7 expression in tamoxifen-treated patients. Moreover, overexpression of the stemness gene, SOX2, was associated with shorter overall survival in those patients.
    DOI:
    10.1007/s43440-021-00346-9
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Hindawi
    Title:

    The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients

    Published date:
    09/16/2021
    Excerpt:
    This study was conducted on 224 ER-positive breast cancer patients...group 1 was tamoxifen sensitive and groups 2 and 3 were tamoxifen resistant...SOX2 and AGR2 biomarkers expression and serum AGR2 level were significantly higher in groups 2 and 3 in comparison to group 1...
    DOI:
    https://doi.org/10.1155/2021/9947540